ClinicalTrials.gg
CompletedNCT01498120Updated Aug 1, 2017Results posted

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

A Phase 2 interventional study of Rotigotine in Restless Legs Syndrome, sponsored by UCB BIOSCIENCES, Inc.. Completed at 5 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2017-08-01.

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.

Enrollment
18th of 19
14 · median 130
Started
2011
with 2 others
Phase 2
6 of 19
none open now
Registered
11th of 19
by date
Lead sponsor
2 of 19
UCB BIOSCIENCES, Inc.

Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 18th largest by enrollment, is one of 3 that started in 2011, is one of 6 in phase 2, and was the 11th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing rotigotine in Restless Legs Syndrome as a file.
02

Study summary

This is a Phase 2, multicenter, open-label, single-arm, optimal dose, long-term follow-up study of monotherapy administration of rotigotine transdermal patch in adolescents with Restless Legs Syndrome (RLS). This study will assess the long-term safety and tolerability of Rotigotine treatment in adolescents with RLS.

Read the detailed description

Study design was changed and an amendment was prepared accordingly.

03

Conditions studied

  • Restless Legs Syndrome

Keywords

  • Rotigotine
  • Restless Legs Syndrome
  • RLS
  • Long-term
  • Adolescents
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Tolerated the first dose level of Rotigotine in a previous study in adolescents with Restless Legs Syndrome (RLS), without meeting withdrawal criteria
  • Is expected to benefit from participation, in the opinion of the investigator
  • Subject/legal representative is considered reliable and capable of adhering to the protocol, visit schedule, and study patch application/removal, according to the judgment of the investigator

Exclusion criteria

Exclusion Criteria:

  • Previously participated in this study
  • Is experiencing an ongoing serious adverse event (SAE) that is assessed to be related to Rotigotine by the investigator or sponsor
  • Pregnant or nursing or is a female of who is not surgically sterile or does not consistently use 2 combined medically acceptable methods of (including at least 1 barrier method), unless not sexually active
  • Any medical or psychiatric condition that, in the opinion of the investigator, can jeopardize or would compromise the subject's ability to participate
  • Active suicidal ideation as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Since the Last Visit" version of the Columbia Suicide Severity Rating Scale (C-SSRS) of the final evaluation visit of the previous Rotigotine study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Optimal dose after titration period 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2)

    Drug: Rotigotine

Interventions

  • Optimal dose after titration period 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) 1 patch /day

06

What researchers measure

Primary outcomes

  1. Number of Subjects Withdrawn Due to An Adverse Event (AE) From Visit 1 (Day 1) Through End of Study

    An Adverse Event is any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: Visit 1 (Day 1) through End of Study (approximately 2 years)

  2. Number of Subjects With At Least One Adverse Event (AE) From Visit 1 (Day 1) to End of Study

    An Adverse Event is any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: From Visit 1 (Day 1) through End of Study (approximately 2 years)

07

Results

Posted Sep 21, 2016

Participant flow

This study started to enroll subjects in USA in January 2012 and concluded in December 2015.

Participant flow — Overall Study
MilestoneRotigotine
Started14
Completed1
Not completed13
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject5
Withdrew: Ae, non-serious non-fatal3
Withdrew: Other4

Outcome measures

PrimaryNumber of Subjects Withdrawn Due to An Adverse Event (AE) From Visit 1 (Day 1) Through End of Study

An Adverse Event is any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
Visit 1 (Day 1) through End of Study (approximately 2 years)
Reported as:
Number · subjects
Number of Subjects Withdrawn Due to An Adverse Event (AE) From Visit 1 (Day 1) Through End of Study
subjectsRotigotine (Safety Set)
Number of Subjects Withdrawn Due to An Adverse Event (AE) From Visit 1 (Day 1) Through End of Study3
PrimaryNumber of Subjects With At Least One Adverse Event (AE) From Visit 1 (Day 1) to End of Study

An Adverse Event is any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
From Visit 1 (Day 1) through End of Study (approximately 2 years)
Reported as:
Number · subjects
Number of Subjects With At Least One Adverse Event (AE) From Visit 1 (Day 1) to End of Study
subjectsRotigotine (Safety Set)
Number of Subjects With At Least One Adverse Event (AE) From Visit 1 (Day 1) to End of Study10

Adverse events

Collected over Adverse Events (AEs) were collected from Visit 1 (Week 0) until Safety Follow Up Visit (up to 25 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine (Safety Set)—0/14 (0%)10/14 (71.4%)
Most frequent other events
Showing 10 of 39
Most frequent other events
EventRotigotine (Safety Set)
NauseaGastrointestinal disorders4/14
VomitingGastrointestinal disorders3/14
Upper respiratory tract infectionInfections and infestations3/14
Urinary tract infectionInfections and infestations2/14
PalpitationsCardiac disorders1/14
Sinus tachycardiaCardiac disorders1/14
Food poisoningGastrointestinal disorders1/14
Application site pruritusGeneral disorders1/14
Febrile disordersGeneral disorders1/14
PyrexiaGeneral disorders1/14

Baseline characteristics

All enrolled subjects who received at least 1 dose of study medication were included in the SS.

Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years14
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(Years)Rotigotine
Mean15.4 ± 1.2
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female10
Male4
08

Study locations

5 sites
  • 012
    Los Angeles, California, United States
  • 009
    Orange, California, United States
  • 014
    Spring Hill, Florida, United States
  • 013
    Indianapolis, Indiana, United States
  • 001
    Destrehan, Louisiana, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2011
First posted
Dec 23, 2011
Start
Dec 2011
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Sep 21, 2016
Last update
Aug 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01498120
Responsible party
Sponsor
First posted
Dec 23, 2011
Start date
Dec 2011
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Sep 21, 2016
Last update
Aug 1, 2017

Study contacts

UCB Clinical Trial Call Center
study director · 1-877-822-9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion